Mirum Pharmaceuticals (MIRM) Competitors $71.52 +2.46 (+3.56%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$71.87 +0.35 (+0.49%) As of 08/22/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MIRM vs. VTRS, ASND, RDY, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, and ROIVShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Mirum Pharmaceuticals vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Mirum Pharmaceuticals (NASDAQ:MIRM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Do institutionals and insiders believe in MIRM or VTRS? 79.9% of Viatris shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer MIRM or VTRS? In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Viatris' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, MIRM or VTRS? Mirum Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Which has preferable earnings and valuation, MIRM or VTRS? Mirum Pharmaceuticals has higher earnings, but lower revenue than Viatris. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$429.16M8.37-$87.94M-$1.21-59.11Viatris$14.12B0.88-$634.20M-$2.90-3.67 Do analysts prefer MIRM or VTRS? Mirum Pharmaceuticals presently has a consensus price target of $74.13, indicating a potential upside of 3.64%. Viatris has a consensus price target of $10.40, indicating a potential downside of 2.35%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Is MIRM or VTRS more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-13.65% -24.76% -8.50% Viatris -24.57%16.54%7.06% SummaryMirum Pharmaceuticals beats Viatris on 12 of the 17 factors compared between the two stocks. Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.47B$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-59.1120.8831.1026.04Price / Sales8.37349.56435.26103.29Price / CashN/A43.1937.7358.48Price / Book14.088.129.536.61Net Income-$87.94M-$54.72M$3.26B$265.56M7 Day Performance5.28%2.63%2.10%1.95%1 Month Performance34.82%2.78%2.82%-0.37%1 Year Performance73.93%11.01%30.56%19.02% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals3.5068 of 5 stars$71.52+3.6%$74.13+3.6%+74.5%$3.47B$429.16M-59.11140News CoveragePositive NewsVTRSViatris1.6454 of 5 stars$10.63+0.2%$10.40-2.2%-9.0%$12.37B$14.74B-3.6732,000Analyst UpgradeASNDAscendis Pharma A/S3.452 of 5 stars$194.08-2.1%$242.93+25.2%+39.4%$12.13B$490.75M-37.611,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories3.1111 of 5 stars$14.26+0.2%$16.95+18.9%-12.1%$11.87B$3.81B21.6027,811News CoveragePositive NewsQGENQIAGEN3.827 of 5 stars$48.66-1.4%$49.69+2.1%+9.4%$10.97B$1.98B28.755,765Positive NewsMRNAModerna4.4344 of 5 stars$28.09+0.2%$43.59+55.2%-66.5%$10.90B$3.24B-3.735,800Analyst ForecastBBIOBridgeBio Pharma4.6808 of 5 stars$49.02-4.5%$61.35+25.2%+97.2%$9.81B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4117 of 5 stars$105.79+0.5%$109.00+3.0%+290.2%$8.96B$42.28M-106.8630Short Interest ↓ELANElanco Animal Health3.0971 of 5 stars$17.72-1.4%$17.33-2.2%+22.4%$8.92B$4.44B20.609,000Analyst DowngradeBPMCBlueprint Medicines0.4892 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4485 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860Insider Trade Related Companies and Tools Related Companies Viatris Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors Moderna Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Elanco Animal Health Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access